As of 2026-03-23, the Intrinsic Value of Akero Therapeutics Inc (AKRO) is -17.79 USD. This AKRO valuation is based on the model Peter Lynch Fair Value. With the current market price of 54.65 USD, the upside of Akero Therapeutics Inc is -132.54%.
Based on its market price of 54.65 USD and our intrinsic valuation, Akero Therapeutics Inc (AKRO) is overvalued by 132.54%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -17.79 - -17.79 | -17.79 | -132.54% |
| P/E | (69.15) - (82.10) | (76.92) | -240.8% |
| DDM - Stable | (35.10) - (154.15) | (94.62) | -273.1% |
| DDM - Multi | (0.50) - (1.65) | (0.76) | -101.4% |
| Market Cap (mil) | 4,498.79 |
| Beta | 0.13 |
| Outstanding shares (mil) | 82.32 |
| Enterprise Value (mil) | 4,322.76 |
| Market risk premium | 4.60% |
| Cost of Equity | 8.59% |
| Cost of Debt | 5.00% |
| WACC | 8.55% |